ArticleDrug delivery2022
D-optimal mixture design for optimization of topical dapsone niosomes: in vitro characterization and in vivo activity against
Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Enhanced Transdermal Delivery of Piroxicam via Nanocarriers, Formulation, Optimization, Characterization, Animal Studies and Randomized Double-Blind Clinical Trial.AAPS PharmSciTech · 2025Trial
- "Acne vulgaris: key insights, treatment, and future prospects".Molecular diversity · 2026Review
- Lipid-Based Nanocarriers as a Promising Delivery System in the Management of Acne.Current pharmaceutical design · 2026Review
- A Systematic Intelligent Optimization Framework for a Sustained-Release Formulation Design.Pharmaceutics · 2025Article
- Preparation, Characterization, and Leishmanicidal Assessment of Silver- and Dapsone-Loaded Niosomes Co-administration:Advanced pharmaceutical bulletin · 2024Article
- Liposomes and Other Nanocarriers for the Treatment of Acne Vulgaris: Improved Therapeutic Efficacy and Skin Tolerability.Pharmaceutics · 2024Review
- An Overview of Biofilm-Associated Infections and the Role of Phytochemicals and Nanomaterials in Their Control and Prevention.Pharmaceutics · 2024Review
- Resolving acne with optimized adapalene microspongeal gel, in vivo and clinical evaluations.Scientific reports · 2024Article
- Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.EXCLI journal · 2024Review
- Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems.Molecular pharmaceutics · 2023Review
- New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective.ACS omega · 2023Review
- Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.BioMed research international · 2023Review
- Atorvastatin-loaded emulsomes foam as a topical antifungal formulation.International journal of pharmaceutics: X · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to illustrate the use of D-optimal mixture design (DOMD) for optimization of an enhancer containing Dapsone niosomal formula for acne topical treatment. Mixture components (MixCs) studied were: Span 20, Cholesterol, and Cremophor RH. Different responses were measured. Optimized formula (OF) was selected to minimize particle size and maximize absolute zeta potential and entrapment efficiency. Optimized formula gel (OF-gel) was prepared and characterized. OF-gel in vivo skin penetration using confocal laser scanning microscopy and activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.